External Publications

Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer

By Erin Bange, MD; Melina E. Marmarelis, MD; Wei-Ting Hwang, PhD; Yu-Xiao Yang, MD, MSCE; Jeffrey C. Thompson, MD; Jason Rosenbaum, MD; Joshua M. Bauml, MD; Christine Ciunci, MD; Evan W. Alley, MD, PhD; Roger B. Cohen, MD; Corey J. Langer, MD; Erica Carpenter, MBA, PhD; Charu Aggarwal, MD, MPH